Cover image for Vol. 110 Issue 5

Edited By: Editor-in-Chief: Robert West, Associate Editor-in-Chief: Thomas F. Babor

Impact Factor: 4.894

ISI Journal Citation Reports © Ranking: 2013: 1/35 (Substance Abuse (Social Science)); 2/18 (Substance Abuse); 13/124 (Psychiatry (Social Science)); 20/136 (Psychiatry)

Online ISSN: 1360-0443

Associated Title(s): Addiction Biology


The worldwide estimate of adults who use amphetamine type stimulants (ATS - specifically methamphetamine and amphetamine excluding MDMA (Ecstasy) is higher than any other class of illicit drug excepting cannabis. ATS users are a varied group, with levels of consumption varying from occasional users to regular users who may meet criteria for abuse or dependence. Primary routes of administration can vary from oral, snorting, smoking to injection. The reasons individuals use ATS can vary and include enabling long work days, relieving boredom, reducing weight, causing euphoria and facilitating sexual behaviors. Behaviorally distinct groups use these drugs and include women, youth, gang affiliated, gay/bisexual men, and laborers/workers.

Differences across defining characteristics of ATS users introduce complexities in understanding its neurobiology and in efforts to respond at every level, including treatment, criminal justice, and policy. In this virtual issue, a compilation of recent papers published over the past five years detail topics related to treatment, to criminal justice, to policy and to behavioral and neurobiological characteristics of ATS users. Taken together, these articles provide readers with a comprehensive overview of the recent evidence and of current opinions central to developments in ATS.

Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES)
McKetin R et al
Addiction 2012; 107: 1998

Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans
Kirkpatrick MG et al
Addiction 2012; 107: 783

What can we learn from the failure of yet another miracle cure' for addiction?
Humphreys K
Addiction 2012; 107: 237

Double-blind placebo-controlled evaluation of the PROMETA (TM) protocol for methamphetamine dependence
Ling W, Shoptaw S, Hillhouse M et al
Addiction 2012; 107: 361

Commentary on Ling et al. (2012): The PROMETA (TM) treatment does not reduce methamphetamine use
Sofuoglu M
Addiction 2012; 107: 370

A systematic review of methamphetamine precursor regulations
McKetin R, Sutherland R, Bright DA et al
Addiction 2012; 107: 1911

Methamphetamine users show greater than normal age-related cortical gray matter loss
Nakama H, Chang L, Fein G et al
Addiction 2012; 107: 1474

The association between spending on methamphetamine/amphetamine and cannabis for personal use and earnings from acquisitive crime among police detainees in New Zealand
Wilkins C, Sweetsur P
Addiction 2012; 107: 789

Mexico's methamphetamine precursor chemical interventions: impacts on drug treatment admissions
Cunningham JK, Borjoquez I, Campollo O et al
Addiction 2012; 107: 1973

Proximity to the US-Mexico border: a key to explaining geographic variation in US methamphetamine, cocaine and heroin purity
Cunningham JK, Maxwell JC, Campollo O et al
Addiction 2012; 107: 1785

Withdrawal symptoms in abstinent methamphetamine-dependent subjects
Zorick T, Nestor L, Miotto K et al
Addiction 2012; 107: 1809

Health outcomes associated with methamphetamine use among young people: a systematic review
Marshall BDL, Werb D
Addiction 2012; 107: 991

Commentary on Marshall et al. (2010): Are long-term negative health consequences of methamphetamine use important to youth?
Rawson RA, Gonzales R
Addiction 2012; 107: 1003

Comparative rates of violent crime among regular methamphetamine and opioid users: offending and victimization
Darke S, Torok M, Kaye S et al
Addiction 2012; 107: 916

Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence
Longo M, Wickes W, Smout M et al
Addiction 2012; 107: 146

A review of the clinical pharmacology of methamphetamine
Cruickshank CC, Dyer KR
Addiction 2012; 107: 1085

Impact of US and Canadian precursor regulation on methamphetamine purity in the United States
Cunningham JK, Liu LM, Callaghan R
Addiction 2012; 107: 441

A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer J, Darke S, Rodgers C et al
Addiction 2012; 107: 224

Aripiprazole for the treatment of methamphetamine dependence: A randomized, double-blind, placebo-controlled trial
Coffin PO, Santos GM, Das M et al